Federal psilocybin policy sprinted in 2026: Executive Order 14401 (April 18, 2026) told FDA to issue national priority vouchers for psychedelics and told the Attorney General to pre-stage rescheduling reviews, FDA finalized its psychedelic trial guidance in July, and it held a public hearing on September 14. Meanwhile Compass Pathways' two pivotal Phase 3 trials — the entire basis of the headlines — have never been peer-reviewed, and the placebo- or low-dose-adjusted effect on the MADRS depression scale is 3.6 to 3.8 points, below the 6-point benchmark often used in depression research. No psilocybin drug is FDA-approved. The EO explicitly creates no rights and reschedules nothing. Psilocybin is Schedule I federally and illegal in New York, where the party is. Nothing that happened in Washington this year changes what is legal for you tonight.
The short answer
The party is legal. The mushrooms are not. An executive order, a finalized FDA guidance and a rolling drug application have changed the regulatory weather, but they have not changed the law, and the pivotal efficacy data behind all of it still has not passed peer review.
ECSTATIC BLOOM is an October 17, 2026 benefit dance party in Bushwick, co-hosted by Brooklyn Psychedelic Society and Chacruna and billed as an unofficial Horizons after-party (https://chacruna.net/ecstatic-bloom-a-psychedelic-soiree-benefit/). To its credit, the listing makes no claims about psychedelics, law or research. It is a fundraiser with a DJ.
So this article is not about the party. It is about the thing the party is dancing on top of — a year in which psilocybin policy moved faster than psilocybin evidence, and the distance between the two got wide enough to trip on.
Here is the gap in three lines. Washington has been busy: a presidential executive order, a final FDA guidance, a public hearing, a rolling new drug application with a priority voucher attached. The journals have not: neither of the two pivotal Phase 3 psilocybin trials has been published anywhere, in any journal, as of this writing. Your legal status is unchanged: psilocybin is Schedule I federally and illegal in New York State.
All three of those are true at the same time. Most coverage picks one.
What Executive Order 14401 actually does
It directs agencies to prepare. EO 14401 orders FDA to give priority vouchers to psychedelics with Breakthrough designation, orders a Right to Try access pathway, directs at least $50 million through ARPA-H toward state programs, and tells DOJ to pre-run rescheduling reviews. Section 6 says it creates no rights.
Executive Order 14401, "Accelerating Medical Treatments for Serious Mental Illness," was signed April 18, 2026. Read it yourself — it is short: https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/
What it directs:
- Sec. 2(a): FDA is to provide Commissioner's National Priority Vouchers to "appropriate psychedelic drugs" holding Breakthrough Therapy designation.
- Sec. 2(b): FDA and DEA are to build a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb-0a) — including the Schedule I handling registrations that would require under 21 U.S.C. 823.
- Sec. 3: HHS, via ARPA-H, is to allocate at least $50 million from existing funds to partner with states running psychedelic programs.
- Sec. 5: the Attorney General, with HHS, is to begin and complete reviews of Schedule I products that have finished Phase 3 for serious mental health disorders, so that rescheduling "may proceed as quickly as practicable" under 21 U.S.C. 811.
Now the parts that get left out of the excited reposts. The order names no specific drug. It sets no calendar deadlines. And Section 6 states in plain text that the order "is not intended to, and does not, create any right or benefit, substantive or procedural."
It approves nothing and reschedules nothing. I also could not verify that anything has actually happened under Sections 3 or 5 — I found no published ARPA-H matching-grant rules and no DEA or Federal Register rescheduling action. An instruction to agencies is a plan, not an outcome.
The pivotal data nobody has peer-reviewed
Compass Pathways reported positive results in both Phase 3 trials of COMP360 psilocybin. The Week 6 MADRS differences were −3.8 points (COMP006) and −3.6 points (COMP005). Both results are company press releases. A PubMed search returns no publication for either trial.
Evidence tier matters here, so let me be explicit: everything in this section is sponsor-reported, not peer-reviewed. Compass Pathways designed, funded and sponsored both trials, and its Chief Medical Officer, Guy Goodwin, is the quoted spokesperson in the release.
COMP006 dosed 581 people across North America and Europe, randomized and double-blind, with two fixed doses three weeks apart: 25 mg (n=296), 10 mg (n=142), 1 mg (n=143). Primary endpoint was change on the Montgomery–Åsberg Depression Rating Scale (see /glossary/madrs). At Week 6, 25 mg beat the 1 mg comparator by 3.8 points (95% CI −5.8 to −1.8, p<0.001). 39% of the 25 mg arm reached a ≥25% MADRS reduction.
COMP005 dosed 258 people (171 COMP360, 87 placebo) with a single 25 mg dose. Week 6 difference: 3.6 points (95% CI −5.7 to −1.5, p<0.001). 25% of the 25 mg arm reached ≥25% reduction. Release: https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx
Three things to hold onto.
One: 3.6 to 3.8 points is small. No minimum clinically important difference was prespecified, and the depression literature puts placebo-adjusted thresholds anywhere from 2 to 9 points, with 6 as a common benchmark. These results clear statistical significance comfortably and land under that 6-point line. I could not find a published, peer-reviewed critique quantifying the Phase 3 result against an MCID, so treat the interpretation as contested rather than settled.
Two: "response" is not remission. The disclosed figure is a ≥25% MADRS reduction — a lower bar than the conventional 50%. Remission rates for COMP005 and COMP006 have not been disclosed at all.
Three: safety was reported, not published. In COMP006's 25 mg arm, 73% of treatment-emergent adverse events occurred on dosing days and 83% resolved within a day; most common were headache, nausea, anxiety and visual hallucination. Six serious adverse events occurred in six participants (2%). COMP005's 25 mg arm logged 11 SAEs in eight participants (5%). Across both trials, the SAE rate for suicidal ideation was under 1%, and the single SAE of suicidal behavior occurred in the 1 mg arm of COMP006; the DSMB chair said there is "no evidence of a clinically meaningful imbalance between treatment arms in suicidality in either study." Compass itself notes the two trials used different comparators and dosing schedules, so the response rates are not cross-comparable.
The only peer-reviewed Compass psilocybin RCT of real size remains the Phase 2b: Goodwin et al., *New England Journal of Medicine*, November 2022, 233 adults with treatment-resistant depression (https://pubmed.ncbi.nlm.nih.gov/36322843/). I could not open that paper this session — the publisher returned 403 — so I am not quoting numbers from it. A search of PubMed for the Phase 3 trials returns nothing. Everything the public knows about the pivotal data comes from the sponsor's own announcements.
Where the approval actually stands
There is no FDA approval. Compass has a rolling NDA submission that was incomplete as of its August 2026 filing, plus a Commissioner's National Priority Voucher that could allow a 1–2 month review. Launch is targeted for H1 2027 and is contingent on both approval and DEA rescheduling.
From Compass's Q2 2026 filing (https://www.sec.gov/Archives/edgar/data/0001816590/000181659026000059/q22026pressrelease.htm): FDA granted rolling NDA submission and review in April 2026, some modules were in, all modules were "on track" for Q4 2026, and COMP360 holds a Commissioner's National Priority Voucher with a potential 1–2 month review after filing. Commercial launch is targeted for the first half of 2027, explicitly "subject to FDA approval and DEA rescheduling." The company also claims roughly 90% of the US patient population lives in states that intend to reschedule within 30 days of DEA action — a company projection about future state behavior, not a legal fact.
The financials are context, not scandal, but they are worth knowing: $433.3 million in cash at June 30, 2026, against a Q2 net loss of $253.8 million ($1.88/share), most of which was a $205.6 million non-cash warrant fair-value loss.
The application was not complete as of August 2026, and I found no October 2026 announcement of completion or approval. Anyone telling you psilocybin is "about to be legal" is describing a sequence with at least two unfinished steps in it.
On FDA's side, two things did finish. The agency finalized "Psychedelic Drugs: Considerations for Clinical Investigations" in July 2026 (docket FDA-2023-D-1987), finalizing the June 2023 draft of the same title: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations. And it held a public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," on September 14, 2026 at White Oak, with the written comment window closing October 5 — now shut. We covered that hearing at /blog/legal-updates/fda-psychedelics-public-hearing-2026. I did not download the final guidance PDF this session, so I am not characterizing what it says about functional unblinding, which remains the central methodological problem for every psychedelic trial.
In New York, none of this is legal
New York has no psilocybin program. S1801A, a $5M pilot for veterans and first responders, was amended and recommitted to the Senate Health Committee on January 9, 2026 and has passed neither chamber. Psilocybin is Schedule I federally, everywhere.
This is the part a Brooklyn party cannot change.
New York State has no legal or regulated psilocybin program of any kind. The closest thing is S1801A (Fernandez), which would fund a $5 million psilocybin-assisted therapy pilot for veterans and first responders through SUNY academic health centers, and which would self-terminate if DEA ever approves psilocybin for medical use. It was amended and recommitted to the Senate Health Committee on January 9, 2026, and it has not passed either chamber: https://www.nysenate.gov/legislation/bills/2025/S1801
Two states run supervised-use programs — Oregon's regulated psilocybin services and Colorado's licensed healing centers (/legal-status/oregon, /legal-status/colorado, and the comparison at /vs/oregon-vs-colorado-psilocybin-therapy). Those are state licenses for supervised sessions inside those states. They are not a federal exemption, they do not travel, and they have nothing to do with buying mushrooms from someone at an after-party. Check your own jurisdiction at /legal-status before you assume anything.
And be clear about the federal layer: psilocybin is Schedule I under the Controlled Substances Act. The executive order did not change that. The vouchers did not change that. A positive press release did not change that.
If you are going anyway, screen first
Psilocybin's worst-documented drug interaction signal involves lithium, and it comes from anecdote-tier data. SSRIs, MAOIs and a personal or family history of psychosis or bipolar I are all reasons to talk to a clinician, not a crowd.
Harm reduction does not require pretending nobody will use anything. It requires naming what is actually known, at the tier it is known at.
Lithium — anecdote tier, but pointed in one direction. Nayak et al., *Pharmacopsychiatry*, 2021, was a retrospective analysis of self-reported posts on Erowid, Shroomery and Reddit — not a clinical study. Of 62 lithium-plus-psychedelic reports, 47% described a seizure and 39% involved medical attention; 0 of 34 lamotrigine reports described a seizure. The authors call their findings provisional, and they are right to (https://pubmed.ncbi.nlm.nih.gov/34348413/). This is the weakest kind of published evidence and also the main published signal that exists. If you take lithium, this is a hard stop: /guides/psilocybin-and-lithium.
SSRIs. Published work on psilocybin alongside serotonergic antidepressants exists — Goodwin et al. in *Neuropsychopharmacology* (2023) on concomitant SSRI use in treatment-resistant depression, and Marwood et al. in *J Psychiatr Res* (2024) on antidepressant discontinuation before psilocybin. I had the citations but not the full texts this session, so I will not summarize their conclusions here. What I will say: discontinuation is itself a medical event (/glossary/ssri-discontinuation-syndrome), and the decision belongs with a prescriber. Start at /guides/psilocybin-and-ssris and /guides/psilocybin-drug-interactions.
MAOIs. I found no quality evidence this session on psilocybin–MAOI interaction. Under-studied means avoid, not "probably fine": /guides/psilocybin-and-maois.
Psychiatric history. A personal or family history of psychosis or bipolar I is a standard exclusion in this class of trial. I did not read the COMP005 or COMP006 protocols this session, so I am not going to quote their exact criteria — but if that history is yours, the correct conversation is with a clinician.
For anything about dose, we keep it in one place and keep it out of articles like this one: /dosage. For setting, sitters and what to do when it goes sideways: /guides/safe-trip and /guides/trip-sitter.
PsyBear takeaways
Policy velocity is not evidence velocity. Enjoy the party, fund the nonprofits, and do not mistake an executive order for a prescription or a press release for a published trial.
1. The executive order changed agency homework, not your legal status. EO 14401 names no drug, sets no deadline, and says in Section 6 that it creates no rights. Psilocybin is still Schedule I.
2. The pivotal trials are unpublished. COMP005 and COMP006 exist in the public record as company press releases and SEC filings. No peer review, no independent read of the raw data, no publication to search for. That is not a conspiracy — it is normal pharma sequencing — but it is a reason to hold the numbers loosely.
3. 3.6 to 3.8 MADRS points is a real effect at the low end of meaningful. Statistically significant, clinically arguable, and reported as ≥25% "response" rather than remission. If a headline told you psilocybin cures depression, the headline went further than the data.
4. No approval exists. The NDA was incomplete as of August 2026, and even the company's H1 2027 launch target is conditioned on FDA approval *and* DEA rescheduling.
5. New York is not Oregon. There is no New York program. S1801A sits in committee. Two states license supervised sessions; neither license works in Brooklyn.
6. Screen before you trust a vibe. Lithium carries the strongest adverse signal in the published literature even though that literature is forum posts. SSRIs and MAOIs need a clinician. A history of psychosis or bipolar I is the standard reason people are excluded from these trials.
Psilocybin is a Schedule I controlled substance under US federal law. It is illegal in New York State, and nothing in Executive Order 14401, FDA's 2026 guidance, or Compass Pathways' trial results changes that. This article is education and commentary on policy documents and company disclosures, not medical advice, and not a suggestion to obtain psilocybin from anyone. If you are on psychiatric medication, talk to your prescriber — not a dance floor.
Key Takeaways
Federal psilocybin policy sprinted in 2026: Executive Order 14401 (April 18, 2026) told FDA to issue national priority vouchers for psychedelics and told the Attorney General to pre-stage rescheduling reviews, FDA finalized its psychedelic trial guidance in July, and it held a public hearing on September 14. Meanwhile Compass Pathways' two pivotal Phase 3 trials — the entire basis of the headlines — have never been peer-reviewed, and the placebo- or low-dose-adjusted effect on the MADRS depression scale is 3.6 to 3.8 points, below the 6-point benchmark often used in depression research. No psilocybin drug is FDA-approved. The EO explicitly creates no rights and reschedules nothing. Psilocybin is Schedule I federally and illegal in New York, where the party is. Nothing that happened in Washington this year changes what is legal for you tonight.
FAQ
- Did Executive Order 14401 make psilocybin legal?
- No. EO 14401, signed April 18, 2026, directs FDA to issue Commissioner's National Priority Vouchers to psychedelic drugs with Breakthrough Therapy designation, directs a Right to Try access pathway, allocates at least $50 million through ARPA-H toward state programs, and tells the Attorney General to pre-run rescheduling reviews. It names no specific drug, sets no deadlines, and Section 6 states it does not create any right or benefit, substantive or procedural. Psilocybin remains Schedule I.
- Have the Phase 3 psilocybin trials been published?
- No. A PubMed search returns no publication for either COMP005 or COMP006. Everything publicly known about the pivotal trials comes from Compass Pathways' press releases and SEC filings. The only peer-reviewed Compass psilocybin RCT of real size is the Phase 2b, published in the New England Journal of Medicine in November 2022.
- How large was the effect in the COMP360 Phase 3 trials?
- Compass reported a Week 6 MADRS difference of 3.8 points for 25 mg versus a 1 mg comparator in COMP006 (95% CI −5.8 to −1.8, p<0.001) and 3.6 points versus placebo in COMP005 (95% CI −5.7 to −1.5, p<0.001). No minimum clinically important difference was prespecified, and depression research commonly uses a 6-point placebo-adjusted benchmark, so the result is statistically significant and clinically arguable.
- Is psilocybin therapy FDA-approved yet?
- No. As of Compass Pathways' August 2026 Q2 filing, the rolling NDA for COMP360 was incomplete, with all modules targeted for Q4 2026. The company holds a Commissioner's National Priority Voucher that could allow a 1–2 month review and targets an H1 2027 launch, explicitly subject to both FDA approval and DEA rescheduling.
- Is psilocybin legal in New York?
- No. New York has no legal or regulated psilocybin program. S1801A, which would fund a $5 million psilocybin-assisted therapy pilot for veterans and first responders through SUNY academic health centers, was amended and recommitted to the Senate Health Committee on January 9, 2026 and has passed neither chamber.
- What is the evidence on mixing psilocybin with lithium?
- The main published signal is Nayak et al., Pharmacopsychiatry, 2021 — a retrospective analysis of self-reported posts on Erowid, Shroomery and Reddit, not a clinical study. Of 62 lithium-plus-psychedelic reports, 47% described a seizure and 39% involved medical attention, versus 0 of 34 lamotrigine reports. The authors call the findings provisional, but it is anecdote-tier data pointing in one direction.